Dyadic's C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa

Stock Information for Dyadic International Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Dyadic International Inc.

Dyadic Attends Investor Events in December
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Dyadic to Present at Industry Events in November
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
Dyadic Appoints Doug Pace to Its Executive Leadership Team
Dyadic to Present at Industry and Investor Events in October
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.